October 19, 2019 : Issue #1012

TOP STORIES — Diabetes News and Research

First Major Breakthrough In 20 Years For The Treatment of Diabetic Kidney Disease and Heart Failure

by George Bakris, MD

Mediterranean Diet and Metabolic Risk Factors in Pregnancy: Esteem Trial

The Risks Associated with CGMs During High-Intensity Exercise

It has been over 6 years since the FDA approved Invokana as the first SGLT-2 inhibitor for the treatment of diabetes. When it was introduced there was a cautious optimism based on the tremendous amount of press concerning the fear of urinary tract infections. Usage was slow at first but as the results on glucose control and weight loss became known, prescribers increased their usage.

In December 2016, Jardiance, another SGLT-2 inhibitor, was given the indication to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease, and prescribing again increased.

Last month the FDA, after looking at the results of the CREDENCE trial, has given Invokana its most important indication yet. Our advisory board member George Bakris, MD, Professor of Medicine, Director, AHA Comprehensive Hypertension Center, The University of Chicago Medicine, has an inside report on the importance of this new indication.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

See article #1.

FDA has approved a new treatment for diabetic kidney disease, which affects one in three patients with type 2 diabetes.

Can the Mediterranean diet decrease the chances of gestational diabetes and preeclampsia?

When using monitored glucose values to alter treatment plans, patients with type 1 diabetes may need to change their monitoring regimen. 

Children born to mothers exposed to lead during pregnancy had four times increased likelihood of having overweight or obesity compared to those whose mothers had lower blood lead levels during gestation, according to a study in JAMA.  Children whose moms had high levels of lead in their blood during pregnancy are more likely than others to carry excess weight by age 8. The conclusion comes from looking at blood tests of more than 1,440 mothers within three days after delivery. Their lead levels were then compared to their offspring’s weight fluctuations during childhood. Researchers noted in a journal news release that when high lead levels were coupled with “adequate” folate levels, the child had a smaller risk of excess weight. 

The study was published Oct. 2 in the journal JAMA Network Open.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Adam Chalela B.S., PharmD Candidate, USF College of Pharmacy Class of 2020

Usif Darwish, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Keri Hames, PharmD Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Kassey  James, Pharm.D. Candidate, LECOM School of Pharmacy

Amber Satz, PharmD Candidate, LECOM School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.